Fresh trending stories, updated frequently
The FDA has approved Wegovy in pill form, a groundbreaking development in obesity treatment. This marks the first daily oral weight-loss medication, enhancing accessibility for patients. Novo Nordisk's shares surged following this approval, positioning the company favorably in the competitive weight-loss market against rivals like Eli Lilly.
The FDA has approved Wegovy, the first oral formulation of a weight-loss medication developed by Novo Nordisk. Set to be available in the U.S. at a price of $149 per month starting next year, this approval represents a significant advancement in obesity management options for patients.
Ride the momentum as stories heat up. Reach readers exploring what’s rising.
All major sources, one page
Feel the mood behind headlines
Know what’s trending, globally
Get summaries. Save time
Switch languages to read your way
Your stories, stored for later
Our system has analyzed 3,678 articles worldwide
~153 per hour
254 trending stories shaping headlines
From breaking news to viral moments
Monitoring 309 trusted sources
Major outlets & specialized publications
Latest update 2 days ago
Always fresh
View the complete directory of tools and products.